other material
confidence high
sentiment positive
materiality 0.80
Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction
RECURSION PHARMACEUTICALS, INC.
- 75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.
- At 25 weeks (12 weeks off therapy), 82% maintained reduction with 53% median decrease from baseline.
- 40% of patients achieved ≥1-point improvement in Spigelman stage (upper GI disease severity).
- Safety profile consistent with MEK1/2 inhibition; no Grade ≥4 TRAEs reported to date.
- Company to engage FDA in 1H26 for registration pathway; trial expanding to ages ≥18.